Inside the Trade: What Bill Ackman Sees in Valeant and Allergan
The Pershing Square activist has avoided investing in drugmakers before, but he and Valeant CEO Michael Pearson understand each other
Michael PeltzAugust 22, 2014
When William Ackman took the stage at the AXA Equitable Auditorium in Midtown Manhattan on April 22, investors were still digesting the news that his firm, Pershing Square Capital Management, had amassed a 9.7 percent stake in Allergan,
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.